pulmonary fibrosis treatment guidelines

Pulmonary Fibrosis Treatment Guidelines

Pulmonary fibrosis treatment guidelines have been developed to diagnose and treat the symptoms of this progressive lung disease. Pulmonary fibrosis is most commonly treated using either medication, which helps to decrease inflammation, or oxygen therapy, which helps to increase the levels of oxygen in the blood. For some people living with pulmonary fibrosis, these treatments can effectively minimize their symptoms. Traditional treatment often has unwanted side effects, however, and does not work for everyone.

At the Lung Institute, our approach to treating pulmonary fibrosis includes a natural alternative to traditional methods: cellular therapy. Using regenerative medicine to treat lung disease has the potential to slow the progression of pulmonary fibrosis and improve the overall function of the lungs, all while helping to manage the symptoms associated with the condition.

We offer two different forms of cellular therapy at the Lung Institute:

  • Venous cellular therapy, in which the cells are derived from the patient’s blood
  • Bone marrow cellular therapy, in which the cells are taken from a small amount of the patient’s bone marrow

Both of these procedures are performed by experienced professionals who utilize minimally invasive techniques, and both types of treatment are administered on an outpatient basis over the course of two days. And because our cellular therapys use autologous cells, or cells derived from the patient’s own body, they have minimal risk of side effects and the risk of rejection is virtually nonexistent.

To learn more about pulmonary fibrosis treatment guidelines as it relates to cellular therapy available at the Lung Institute, call our team today at (800) 729-3065.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.